Aurinia Pharmaceuticals AUPH Visp, Switzerland — Finance right-of-use lease assets
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Aurinia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:FinanceLeaseRightOfUseAsset.
The official record: Aurinia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aurinia Pharmaceuticals's visp, switzerland — finance right-of-use lease assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aurinia Pharmaceuticals's visp, switzerland — finance right-of-use lease assets?
- Aurinia Pharmaceuticals (AUPH) reported visp, switzerland — finance right-of-use lease assets of $69.5M in Q1 2026.
- How has Aurinia Pharmaceuticals's visp, switzerland — finance right-of-use lease assets changed year-over-year?
- Aurinia Pharmaceuticals's visp, switzerland — finance right-of-use lease assets decreased by 20.0% year-over-year, from $86.9M to $69.5M.
- What does visp, switzerland — finance right-of-use lease assets mean?
- Represents the carrying value of right-of-use assets recognized on the balance sheet for finance leases located in the Visp, Switzerland segment. This reflects the capitalized value of the company's right to use leased property or equipment over the lease term. It provides insight into the scale of the company's asset base that is financed through leasing arrangements rather than direct ownership.